On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association

  • A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023
  • The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery
  • The data supports Longeveron’s ongoing ELPIS II study, which has exceeded its 50% enrollment threshold
  • The company believes the long-term follow-up data underscore the potential for Lomecel-B(TM) as a much-needed therapeutic innovation for HLHS patients
  • Historical results from outside studies have shown that children with HLHS who are undergoing Stage II surgery have approximately 20% mortality by 5 years of age

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions including hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty has evaluated – and still is evaluating – its lead investigational therapeutic candidate Lomecel-B(TM), an allogeneic, bone marrow-derived medicinal signaling cell (“MSC”) therapy product, in multiple clinical trials.

One of these trials, titled ELPIS I, was a Phase 1, open-label single-arm study whose final results Longeveron announced in September 2021 (https://ibn.fm/iL6z8). ELPIS I was designed to assess the safety and potential efficacy as of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with HLHS during Stage II surgeries at approximately 4 months of age. The study met the primary safety endpoint: no major adverse cardiac events or any treatment-related infections during the first month post-treatment were reported. Moreover, secondary endpoints measured per protocol suggested Lomecel-B(TM) injection may improve patient long-term clinical outcome post-surgery.

While the positive results permitted the transition to a Phase 2 randomized, double-blind, controlled trial, ELPIS II, with enrollment commencing in July 2021 (https://ibn.fm/HuGcD), investigators elected to extend follow-up of the 10 infants after ELPIS I came to its planned end for a total period of five years. More than two years later, at the annual Scientific Sessions of the American Heart Association (“AHA”) held November 11-13, 2023, in Philadelphia, Pennsylvania, a poster about Longeveron’s extended long-term follow-up data was presented. (Additional long-term follow-up is still ongoing in the ELPIS I children.)

The poster, titled Long-term Transplant-free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-based Therapy and authored by Sunjay Kaushal, M.D., Ph.D., the principal investigator of the ELPIS I study, and colleagues, showed that all the 10 children survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery.

The transplant-free survival follow-up on all patients enrolled in the study is ongoing.  Moreover, the average age at the time of the last follow-up visit was 4.5 years, with 2 patients being 5 years of follow-up, according to the company.

“Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants, and reinforce potential survival benefit of Lomecel-B(TM) for patients with HLHS,” commented Joshua M. Hare, Longeveron’s Co-Founder, Chief Science Officer, and Chair of the Board of Directors. “These data represent an additional up to 2 years of follow-up data, which point to the potential of Lomecel-B(TM) in this indication and provide support for our ongoing ELPIS II study, which has exceeded its 50% enrollment threshold. We anticipate completing enrollment in this trial in 2024.”

FDA granted Rare Pediatric Disease Designation (“RPD”), Orphan Drug Designation, and Fast Track designation to Longeveron’s Lomecel-B(TM) for treatment of HLHS. 

HLHS refers to cardiac malformations characterized by underdevelopment or absence of the left ventricle. Before the 1980s, HLHS was associated with 95% mortality within the first month of life. But in the last two decades of the 20th century, there was remarkable progress in the management of children born with HLHS, thanks to the introduction and successful implementation of operative reconstructive procedures, according to a 2000 study (https://ibn.fm/xo0Cy).

These procedures, which are still used to date, are performed in three stages. The final result is a reconstructed heart in which the right ventricle – which ordinarily pumps deoxygenated (venous) blood to the lungs – is now responsible for pumping oxygenated blood to the body through a reconstructed aorta, with venous blood returning directly to the lungs without going through the heart chambers.

While the operative procedures have helped lower mortality, some patients who have undergone surgeries still succumb to HLHS. According to a 2015 study (https://ibn.fm/r54vE), “The highest mortality for infants with HLHS undergoing surgical intervention is with Stage 1 palliation and the interstage period between Stage I and Stage II surgery, both done in the first year of life.”

Furthermore, Kaushal explained, “Historical data collected by the National Heart, Lung, and Blood Institute (‘NHLBI’) has shown that more than 15% of HLHS patients either required a heart transplant or died from their illness 12 months after having undergone Stage 2 surgery. Additional historical data from the NHLBI-sponsored Single Ventricle Reconstruction (‘SVR’) trial – the largest HLHS trial to date, with enrollment of more than 500 patients – shows that patients undergoing Stage II surgery have approximately 15% mortality by year 3 after surgery, which increased to approximately 20% mortality by 5 years.”

These statistics underscore the high unmet need among children with HLHS. Fortunately, the extended follow-up data, which show the 100% survival rate of ELPIS I patients up to 5 years post-treatment, highlight the opportunity for Lomecel-B(TM) as a much-needed therapeutic innovation for this patient group.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

Forward-Looking Statements

Certain statements in this document that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur at all, or that any such transaction will occur on the timelines, in the manner, or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Reports on Form 10-Q filed with the SEC. The forward-looking statements contained in this presentation are made as of the date of this presentation, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

Archives

Select A Month
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered